The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tseng, C.-T. K.
Right arrow Articles by Peters, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tseng, C.-T. K.
Right arrow Articles by Peters, C. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2005, 174: 7977-7985.
Copyright © 2005 by The American Association of Immunologists

Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection1

Chien-Te K. Tseng2,*,{dagger}, Lucy A. Perrone{dagger}, Hongbing Zhu*, Shinji Makino*,{dagger} and Clarence J. Peters*,{dagger}

Departments of* Microbiology and Immunology and{dagger} Pathology, University of Texas Medical Branch, Galveston, TX 77555


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Severe acute respiratory syndrome (SARS) caused by a novel human coronavirus (CoV), designated SARS-CoV, is a highly contagious respiratory disease with the lungs as a major target. Although the exact mechanism of SARS-CoV pathogenesis remains unknown, an intense, ill-regulated local inflammatory response has been suggested as partially responsible for the devastating lung pathology. We investigated the interaction of SARS-CoV with human macrophages (M{phi}) and dendritic cells (DC), two key innate immune cells of the host immune system, by focusing on their susceptibility to viral infection and subsequent responses (e.g., phenotypic maturation, T cell-priming activity, phagocytosis, and cytokine production). We found neither cell to be permissive for SARS-CoV replication. However, incubation of M{phi} and DC with live, but not gamma irradiation-inactivated, viruses appeared to better sustain their viability. Also, exposure to infectious SARS-CoV led to the phenotypic and functional maturation of DC, with regard to MHC class II and costimulatory molecule expression, T cell-stimulatory capacity, and cytokine production, respectively. Cytokine production was also observed for M{phi}, which were refractory to cell surface phenotypic changes. Strikingly, live SARS-CoV could further prime cell types to respond to a suboptimal dose of bacterial LPS (100 ng/ml), resulting in massive release of IL-6 and IL-12. However, the endocytic capacity (e.g., Ag capture) of M{phi} was significantly compromised upon exposure to infectious SARS-CoV. This study is the first demonstration that although SARS-CoV does not productively infect human M{phi} or DC, it appears to exert differential effects on M{phi} and DC maturation and functions, which might contribute to SARS pathogenesis.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The outbreak of severe acute respiratory syndrome (SARS),3 an acute and highly contagious pulmonary illness that spreads primarily via the respiratory route, has had a devastating social, economic, and medical impact worldwide (1). The causative agent of SARS was quickly identified as a novel cornonavirus (CoV), now designated SARS-CoV, and genomes of a number of isolates were subsequently sequenced through an intense and unprecedented international effort (2, 3, 4, 5, 6). Additionally, angiotensin-converting enzyme 2 (ACE2) was recently identified as a functional receptor responsible for the entry of SARS-CoV into permissive cells, providing an important clue to the cellular and tissue tropism of this virus (7). Despite these remarkable achievements, the pathogenesis of SARS-CoV is still not understood.

The outcome of virus-host interaction depends on many factors of both viral and cellular origin. SARS is a highly contagious and life-threatening respiratory disease with the lower respiratory tract (e.g., the lungs) as its main target of the pathogenic process (3, 8, 9). Immunopathological examination of postmortem lung tissues from SARS patients revealed diffuse alveolar damage with prominent pneumocytic hyperplasia and accumulation of alveolar and interstitial macrophages (M{phi}), as well as other pathological manifestations characteristic of acute respiratory disease syndrome resulting from massive inflammatory responses in the lungs. Intriguingly, these pulmonary manifestations usually occur after the clearance of viremia and in the absence of a consistent detection of other infectious agents, suggesting that an intense local inflammatory response, not directly induced by SARS-CoV or other opportunistic pathogens, could be responsible for the devastating outcome of SARS-CoV infection. The likelihood of SARS being an immune-mediated disease is also supported by the observation of a transient lymphopenia, especially in CD4+ and CD8+ T cells early in the SARS episode, and elevated serum levels of inflammatory cytokines in SARS patients (10, 11, 12, 13).

M{phi} and DC are two key cellular elements of the innate immune system with various effector functions, e.g., phagocytosis, Ag presentation, and cytokine production, facilitating their indispensable role in regulating the interplay between innate and adaptive immune responses. In addition, the fact that most resting M{phi} and immature DC reside at sites of an interface with the environment, such as the mucosal epithelium, alveoli of the respiratory tract, and the skin, where most infections occur, makes them among the first and ideal targets for viral exploitation, contributing to viral pathogenesis (14, 15). Consequently, interactions between viruses and M{phi} or DC have been studied extensively for clarifying the pathogenesis of viral infections. Clearly, viruses can affect the biology of M{phi} and DC in several ways. For instance, the persistent viruses, like human CMV and murine CMV, may be sequestered within these cells and impair their functions (16, 17). Cytolytic viruses can induce cytopathic effects on M{phi} and DC, as shown with measles, vaccinia virus, and influenza virus (18, 19, 20). Importantly, viral infections can modulate host immune responses by either enhancing or dampening the effector functions of M{phi} and DC, causing immunopathogenesis and/or immunoevasion (18, 21, 22, 23, 24, 25). Additionally, M{phi} and DC can also harbor infectious viruses, serving as reservoirs for further dissemination (14, 26, 27).

Given the pivotal roles of M{phi} and DC in host defense against viral infections, it is important to determine whether SARS-CoV can interfere with the function of these two critical innate immune cells, thereby influencing the outcome of the infection. This information is crucial not only for understanding SARS-CoV pathogenesis, but also for devising successful therapeutic strategies. Thus, in the present study we investigated the susceptibility of primary human M{phi} and DC to SARS-CoV infection and also analyzed their responses by examination of their expression of costimulatory molecules, secretion of inflammatory cytokines, phagocytic capacity, and the potential for priming naive T cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Virus

The Urbani strain of SARS-CoV, kindly provided to us by Dr. T. G. Ksiazek at the Centers for Disease Control (Atlanta, GA), was used throughout this study. The original stock of SARS-CoV was subjected to two additional passages in Vero E6 cells, generating a cell-free viral stock with a titer expressed as 50% tissue culture infectious dose (TCID50)/ml sample (1 x 107 TCID50/ml), which was stored at –80°C. In addition, aliquots of this infectious stock were also irradiated (2 x 106 rads) from a cobalt-60 source, according to a predetermined kill curve, and used as an inactivated SARS-CoV (gamma-inactivated) control in this study. All experiments involving infectious virus were conducted at the University of Texas Medical Branch (Galveston, TX) in an approved biosafety level 3 laboratory with medical monitoring of staff.

Virus titration

Supernatants collected at different time points postinfection were assayed for infectious viral titers in a TCID50 assay on permissive Vero E6 cell monolayers in 24-well plates with 10-fold diluted samples. The titer of individual samples was expressed as TCID50 per milliliter of sample.

Detection of SARS-CoV replication by quantitative real-time PCR

Total RNA was isolated from mock-infected and SARS-CoV-infected Vero E6 or U937 cells (106 cells) at indicated time points after infection by a standard protocol using TRIzol reagent (Invitrogen Life Technologies). Contaminating genomic DNA was digested with DNase I during the extraction procedure. The primer pair and probe for detecting SARS-CoV-specific subgenomic mRNA 5 (M protein) were: forward 5'-AGGTTTCCTATTCCTAGCCTGGATT, reverse 5'-AGAGCCAGAGGAAAACAAGCTTTAT, and the sequence of ACCTGTTCCGATTAGAATAG as detection probe, all of which were derived by using Assays-by-Design (part no. 4331348; Applied Biosystems). The predeveloped primer set and TaqMan probe for 18 S rRNA (part no. 4319413E) were used as the endogenous control. One-step, real-time PCR was used to quantify the expression of SARS-CoV-specific subgenomic mRNA 5 sequences at indicated time points after infection. Briefly, 80 ng of RNA was transferred to separate tubes for amplifying the target gene (SARS-CoV) and endogenous control (18 S rRNA), respectively, by using a TaqMan one-step real-time PCR master mix reagent kit (part no. 4309169). The cycling parameters for one-step real-time PCR were: reverse transcription at 48°C for 30 min, AmpliTaq activation at 95°C for 10 min, denaturation at 95°C for 15 s and annealing/extension at 60°C for 1 min. A total of 40 cycles was performed on an ABI PRISM 7000 real-time thermocycler (Applied Biosystems) following the manufacturer’s instructions. DNA fragments encoding SARS-CoV-specific subgenomic mRNA 5 were amplified in triplicate with 18 S rRNA and relative mRNA levels for each sample were calculated as: {Delta} cycle threshold (Ct) = Ct(SARS-CoV) – Ct(18 S rRNA). Ratio of mRNA in infected cells to mRNA in mock-infected cells = 2–({Delta}Ct infected – {Delta}Ct mock).

M{phi} and dendritic cells (DC)

Human macrophage-like cell line U937 and DC-like cell line KG-1 (American Type Culture Collection) were grown in RPMI 1640 medium supplemented with 10 and 20% heat-inactivated (56°C, 30 min) FCS, respectively, and with penicillin (100 U/ml), streptomycin (100 µg/ml), and L-glutamine (2 mM) in a humidified 5% CO2-95% air incubator. Primary M{phi} and DC were prepared from highly enriched peripheral monocytes. Briefly, PBMC were purified from the peripheral blood of healthy individuals by Ficoll-Paque gradients (Amersham Biosciences). CD14+ monocytes were purified from PBMC by negative selection using a combination of an Ab mixture for the enrichment of human monocytes and a magnetic column separation system (StemCell Technologies), as previously described (28). We routinely obtain >95% purity of CD14+ monocytes, as assessed by flow cytometry. We followed the well-established protocol to generate M{phi} and DC from highly enriched CD14+ monocytes, as described elsewhere (29, 30, 31). Briefly, monocytes were set up in 24-well culture plates at 2 x 105 cells/ml in complete RPMI 1640/10% FCS (R-10) medium supplemented with GM-CSF (500 U/ml) alone or a mixture of GM-CSF (1000 U/ml) and IL-4 (500 U/ml) to generate M{phi} and DC, respectively. Cytokines were replenished every 3–4 days. Cells were harvested at 6–7 days of culture for their morphologic and phenotypic characterization. GM-CSF-stimulated monocytic cells consistently gave rise to highly adherent CD14+CD1a–CD40lowCD86–HLA-DR+ cells; whereas the nonadherent or loosely adherent CD14low/–CD1a+CD40+/lowCD86+/lowHLA-DR+/lowCD83– cells, typical of immature DC, were derived from GM-CSF/IL-4-driven cultures.

Viral infections

M{phi} and DC were infected with infectious SARS-CoV at a multiplicity of infection (MOI) of 1 unless indicated otherwise or incubated with gamma-inactivated virus at 37°C for 1 h. Mock-infected cells exposed to a similar volume of medium were included as controls. Cells were then washed twice with PBS to remove unbound virions and cultured at 37°C in RPMI 1640 medium supplemented with 10% heat-inactivated FCS (R-10) medium for various time periods. For some experiments, infected cells were cultured in the R-10 medium supplemented with exogenous cytokines used for their in vitro differentiation, e.g., GM-CSF for M{phi} and GM-CSF plus IL-4 for DC. The cell-free supernatants and cells were harvested at indicated time points after infection for subsequent use in viral titration, cytokine profiling, and cell surface phenotyping.

Phenotyping of M{phi} and DC

The cell surface phenotypes of M{phi} and DC were determined with a panel of Abs and flow cytometry. Briefly, aliquots of 105 cells were resuspended in 100 µl of staining solution, e.g., PBS with 2% FCS and 0.2% sodium azide, followed by incubation with FITC-conjugated mouse mAbs against human CD40, CD86, CD1a, CD83, and HLA-DR molecules. Cells stained with isotype-matched, FITC-labeled control Abs were included as nonspecific Ab-binding controls. All of these Abs were purchased from Caltag Laboratories. In some experiments, M{phi} and DC were also stained for expression of the TLR4 using FITC-labeled specific mAb (Apotech). After washing to remove unbound Abs, cells were resuspended in 500 µl of 1% paraformaldehyde in PBS, incubated overnight at 4°C, a condition shown to completely inactivate at least 107 TCID50 SARS-CoV (data not shown), before analyzing with FACScan and CellQuest software (BD Biosciences). Positive and negative staining of cells was decided by comparison with those of control Abs. In addition, the mean fluorescence intensity (MFI) values of individual molecules were also used to monitor the changes in the expression of surface molecules.

Allogeneic CD4+ T cell proliferation

Human PBMC were isolated from healthy individuals by Ficoll-Paque gradient centrifugation and CD4+ T cells were purified by negative selection with a combination of Ab mix for enriching human CD4+ T cells and a magnetic column (StemCell Technologies), as previously described (32). DC were preincubated with infectious virus or with gamma-inactivated virus or left untreated for 2 days, in 200 µl of R-10 medium in 96-well plates for a total of 6 days. A fixed number of allogeneic CD4+ T cells (1 x 105/well) were cocultured with these DC at various ratios. The triplicate cultures were pulsed with 1 µCi/well [3H]thymidine (New England Nuclear) for the last 12–16 h in the culture. The total incorporation of [3H]thymidine was determined by liquid scintillation counting, and expressed as cpm.

Detection of IL-6 and IL-12

Cell-free supernatants, harvested at indicated time periods from different cultures of M{phi} and DC, were subjected to gamma irradiation. The dosage of 2 x 106 rads was according to our kill curve studies against SARS-CoV, to ensure the absence of infectious virus, as evident by the absence of infectivity of irradiated samples in permissive Vero E6 cells, before assessing cytokine content in a biosafety level 2 laboratory. The amount of IL-6 and IL-12 in the supernatants was assessed by ELISA, as previously described (32, 33). Both capture mAb and biotinylated detection mAb for human IL-6 and IL-12p40 subunits were purchased from BD Pharmingen and used at the concentrations recommended by the manufacturer. Various concentrations of recombinant IL-6 and IL-12, ranging from 50,000 to 50 pg/ml, were included in the assay as the standard. Avidin-conjugated peroxidase and chromogenic substrate o-phenylenediamine dihydrochloride were obtained from Sigma-Aldrich. Spectrophotometer analysis was performed at a 405 nm wavelength on an Emax spectrophotometer (Molecular Devices) using Softmax Pro software (Molecular Devices). The levels of IL-6 and IL-12 were expressed as the mean ± SD of duplicate samples.

Assessing phagocytosis by flow cytometry

Pellets of differentially treated M{phi} (2 x 105 cells/pellet) were resuspended in 500 µl of R-10 medium in 1.5-ml Eppendorf tubes containing FITC-dextran (m.w. = 40,000, 40 µg/ml; Sigma-Aldrich) and were incubated at 37°C (or at 4°C for control) for 1 h. The cells were washed five times with cold R-10 medium and fixed with 2% paraformaldehyde, and the amount of the accumulated intracellular fluorescent probe was determined using a FACScan flow cytometer (BD Biosciences).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
SARS-CoV fails to productively infect human M{phi} and DC

M{phi} and DC are two of the most prominent cellular elements of innate inflammatory responses. To study the potential effect of SARS-CoV on the host defense system, we first determined whether this virus could productively infect M{phi} and DC. For this study, we initially infected primary M{phi} and DC, all of which were derived from the 6- to 7-day cytokine-driven CD14+ monocytic cell cultures, as described in Materials and Methods. Permissive Vero E6 cell monolayers infected with SARS-CoV at an MOI of 1 were included as the positive control. Cell-free supernatants were harvested at indicated time points after infection and the titers of infectious viral particles were assessed by a standard TCID50 assay on Vero E6 cell monolayers. As expected, Vero E6 cells were highly permissive to SARS-CoV infection, in which a maximum viral yield (1–5 x 107 TCID50/ml) could be consistently detected between 24 and 48 h after infection (Fig. 1). Additionally, foci of cytopathic effects in infected monolayers (cellular roundup and detachment) could be observed within the first 24 h after infection, which subsequently reached 70–80% within 36–48 h (data not shown). In contrast to the strikingly early burst of viral replication in Vero E6 cells, SARS-CoV did not seem to replicate in M{phi} and DC. As shown in Fig. 1, representative of eight independent experiments using cells derived from six different individuals, the titers of infectious virus particles in the supernatants harvested over time after infection steadily dropped from 105.5 to 106 TCID50/ml at day 0 (e.g., 1 h after infection) to become undetectable and 102 TCID50/ml at day 5 for M{phi} and DC, respectively. The nonproductive nature of SARS-CoV infection was also observed in repeated experiments by using M{phi}-like U937 cells and DC-like KG-1 cells, showing very similar kinetics of decreasing infectivity in the supernatants (data not shown). To determine whether a small fraction of cells might be permissive for SARS-CoV, which may not be readily detected by the TCID50 assay, we used highly sensitive real-time PCR to quantify the expression of SARS-CoV-specific subgenomic sequences over time in infected cells. We chose monocytic U937 or DC-like KG-1 cells over primary M{phi} and DC to ensure sufficient cell numbers for this study. We infected U937, KG-1, and Vero E6 cells with SARS-CoV (MOI = 1). Total RNA extracted from infected cells at indicated periods after infection were subjected to amplification and analysis of SARS-CoV-specific subgenomic mRNA 5 (M protein) by quantitative real-time PCR. As shown in Fig. 2, a dramatic increase in the copy number of mRNA 5 could be readily detected in permissive Vero E6 cells at 12 and 24 h after infection, paralleling the viral replication. Although mRNA 5 was readily detected in U937, KG-1, and Vero E6 cells at both 1 and 20 h after infection by qualitative PCR (data not shown), an increase in its copy number over time was not found in U937 cells or in KG-1 cells. Taken together, these results indicate that neither M{phi} nor DC are permissive to SARS-CoV replication.



View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 1. Primary human M{phi} and DC fail to support the replication of SARS-CoV. M{phi}, DC, and permissive Vero E6 cells were infected with SARS-CoV at a MOI of 1.0 for 1 h. Unbound viral particles were removed by washing (two times) with PBS. Infected cells were subsequently cultured in duplicate with 24-well plates at a density of 1 x 106/ml (M{phi} and DC) or ~5 x 105/well of Vero E6 monolayer. Supernatants were removed at days 0 (1 h after adsorption), 1, 3, and 5 after infection, and the virus titer was determined by the standard TCID50 assay using Vero E6 cells as indicator cells. Virus titers were expressed as mean ± SD of duplicate samples. The growth curve of SARS-CoV in Vero E6 cells was one representative of two independent experiments, and the virus titers in M{phi} and DC were a representative of eight independent experiments using cells derived from six different individuals.

 


View larger version (11K):
[in this window]
[in a new window]
  		FIGURE 2. Detection of subgenomic mRNA 5 in SARS-CoV-infected Vero E6, U937, and KG-1 cells by quantitative real-time PCR. Vero E6, U937, and KG-1 cells were harvested at 1, 12, and 24 h after infection with SARS-CoV (MOI = 1). Total RNA was subsequently extracted at each time point and subjected to quantitative real-time PCR amplification for virus-specific subgenomic mRNA 5 (M protein) species. The intensity of mRNA 5 expression was normalized to 18 S RNA. The average of mRNA 5 signals in two independent experiments is depicted.

 
SARS-CoV does not add to the cell death of cultured M{phi} and DC

Cell death is a likely outcome of viral infection, as exemplified by the apparently lytic infection of SARS-CoV in Vero E6 cells. Thus, we investigated whether SARS-CoV could affect the viability of M{phi} or DC. For these experiments, uninfected and SARS-CoV-infected cells (MOI = 1) were cultured in 24-well plates for 72 h in R-10 medium with or without the presence of exogenous cytokines used for in vitro differentiation (e.g., GM-CSF and GM-CSF plus IL-4 for M{phi} and DC, respectively). The cell viability in the differential cultures was determined by a trypan blue exclusion technique. As shown in Fig. 3, total viable cells recovered from mock-infected cultures grown in R-10 medium alone (n = 4) were ~20 and 50% of the original cellular input for DC and M{phi}, respectively. To our surprise, these poor recoveries of viable cells were improved to 37% (DC, p ≤ 0.08) and 65% (M{phi}) upon incubation with SARS-CoV. Because various cytokines are known to prevent cell death, the increased viability of M{phi} and DC due to SARS-CoV exposure may suggest that this virus could be capable of inducing the release of cytokines from these cells. The requirement of soluble factors for better sustaining the viability of M{phi} and DC was supported by the dramatically increasing viability of mock-infected cells cultured in the presence of exogenous cytokines (n = 2), in which the viability was increased from 20 to 50% for DC (p ≤ 0.05) and from 50 to 68% for M{phi}. However, the difference in the viable cell recovery between mock-infected and infectious virus-exposed cells cultured in exogenous cytokine-containing R-10 medium was not significant (e.g., 50 vs 55% and 65 vs 68% for DC and M{phi}, respectively). Although the molecular basis for the elevated viability in both M{phi} and DC remains to be determined, our results clearly indicate that exposure of these cells to SARS-CoV does not add to the mortality of cultured M{phi} and DC.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 3. SARS-CoV does not add to the mortality of infected DC and M{phi}. DC and M{phi} were either mock-infected or infected with SARS-CoV at an MOI of 1 at 37°C for 1 h. After washing (two times) to remove unbound virus, cells were incubated in R-10 medium with (n = 2) or without (n = 4) exogenous cytokines used for in vitro differentiation (e.g., GM-CSF/IL-4 and GM-CSF alone for DC and M{phi}, respectively). n, Number of independent experiments. Total numbers of viable cells recovered from uninfected and infected cultures were determined by trypan blue exclusion technique at 72 h after infection, and expressed as the percentage of the original cellular inputs (mean ± SEM). *, p ≤ 0.05; Student’s t test, compared with medium controls.

 
In addition to causing cell death, many viruses have been shown to modulate various functions of M{phi} and DC, including activation, differentiation, maturation, and cytokine production (14, 21, 34). Importantly, the ability to alter the function of host cells by some viruses appears to be independent of viral replication (35, 36). Therefore, we designed a series of experiments, as described below, aimed to determine whether SARS-CoV could have any impact on the function of M{phi} and DC.

SARS-CoV induces the phenotypic maturation of DC, but not M{phi}

Activation and maturation of M{phi} and DC are essential for initiating and/or promoting Ag-specific, T cell-mediated responses, largely due to their enhanced expression of costimulatory molecules, a process known as "phenotypic maturation" in DC (37, 38). We thus investigated whether SARS-CoV has the potential to influence this maturation process in M{phi} and DC. For these experiments, mock-infected cells and cells that were infected with live virus (MOI = 1) or with gamma-inactivated virus for 72 h were analyzed by flow cytometry for their expression of various cell surface molecules, including costimulatory (CD40, CD86), MHC (HLA-DR), and a marker for mature DC (CD83). As shown in Fig. 4A, representative of six independent experiments, the expression of CD40 and CD86 was not significantly altered in M{phi} infected with either inactivated or live viruses, when compared with uninfected cells. The expression of HLA-DR on live virus or inactivated virus-treated M{phi} was either unaffected (n = 4) or reduced (n = 2) in six independently conducted experiments. In contrast to M{phi}, whose expression of costimulatory molecules, e.g., CD40 and CD86, appears to be rather refractory to manipulation, in seven of nine independent experiments using DC derived from six different individuals, an increased expression of at least one of the costimulatory molecules tested as a result of exposure to live SARS-CoV could be readily detected. As shown in Fig. 4B, representative of seven independent experiments demonstrating an enhanced expression of costimulatory molecules, the expression of CD40, CD86, HLA-DR, and CD83 was increased in DC incubated with live virus, when compared with mock-infected or inactivated virus-exposed DC. SARS-CoV most frequently enhances the expression of CD40 and CD83, among various markers tested, suggesting that such a virus-mediated enhancement in the expression of costimulatory molecules appears to be selective rather than global. Although inactivated virus did not exhibit any effect on the phenotypic maturation of DC in most of the experiments, a slight increase in the expression of selected molecules was occasionally observed. We also noted that no changes in the cell surface molecule expression were observed in two of nine experiments (data not shown), suggesting that DC that were derived from different individuals might not be universally responsive to SARS-CoV.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 4. Flow cytometric analysis of surface molecule expression on differentially infected M{phi} and DC. M{phi} and DC were infected with live SARS-CoV or with gamma-inactivated SARS-CoV (MOI = 1). The expression of CD40, CD86, HLA-DR, and/or CD83 molecules on the surface of uninfected, inactivated virus-infected, and live virus-infected M{phi} and DC were analyzed by flow cytometry. Data presented are the histogram plots of FACS analysis for M{phi} (A) and DC (B) with shown percentages of positively stained cells and their MFI. A representative of six independent experiments was presented.

 
SARS-CoV activates the production of IL-6 and IL-12 by M{phi} and DC

Both M{phi} and DC have been identified as key producers of innate inflammatory cytokines in response to microorganisms and/or their microbial products, such as bacterial LPS (37, 38, 39). To investigate whether SARS-CoV could modulate their intrinsic ability to produce cytokines, M{phi} and DC were incubated with live or inactivated SARS-CoV at an MOI of 1 for 48 h, followed by an additional 36-h incubation with or without a suboptimal dose of bacterial LPS (100 ng/ml). The contents of IL-12 (p40 subunit) and IL-6 in the resulting culture supernatants were assessed by ELISA.

As shown in Fig. 5, representative of six independent experiments using cells derived from five different individuals, mock-infected M{phi} and DC spontaneously released low, but detectable, amounts of IL-12 and IL-6. Stimulation of M{phi} and DC with a suboptimal dose of LPS resulted in a slight increase in secretion of both IL-12 and IL-6 in DC and of IL-6 but not IL-12 in M{phi}. Additionally, neither spontaneous nor LPS-mediated IL-12 and IL-6 production was significantly altered in DC exposed to inactivated virus. However, there was a 2-fold increase in LPS-mediated IL-6 production in inactivated virus-exposed M{phi}, compared with mock-infected cells. Incubation of either M{phi} or DC with live virus consistently resulted in a slight increase in the production of both IL-12 and IL-6, when compared with those of mock or inactivated virus-exposed cultures. Remarkably, when live virus-exposed M{phi} and DC were cocultured with a suboptimal dose of LPS (100 ng/ml), a dramatic increase in both IL-12 and IL-6 production was observed, suggesting that infectious SARS-CoV can prime these two innate immune cells to a high cytokine production in response to secondary activation signals provided by LPS.



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 5. SARS-CoV affects spontaneous and LPS-induced IL-12 and IL-6 production by M{phi} and DC. Uninfected, inactivated SARS-CoV-infected, and live SARS-CoV-infected primary human M{phi} (A and B) and DC (C and D) were stimulated with a suboptimal dose of LPS (100 ng/ml) at 48 h after infection or left untreated. The supernatants were harvested at 36 h after LPS stimulation and their contents of IL-12 and IL-6 measured by ELISA. Data shown are the mean ± SD of duplicate cultures in individual experiments. These results are representative of six independent experiments using cells derived from five different individuals. *, p < 0.05; **, p < 0.01 by Student’s t test, compared with mock-infected controls.

 
TLR4 is constitutively expressed on M{phi} and DC and is a key LPS-responding molecule. We, thus, investigated whether the highly enhanced cytokine production in response to LPS by live virus-infected cells could be correlated with the extent of TLR4 expression. As shown in Fig. 6, representative of two independent experiments, ~17% of M{phi} and DC constitutively expressed TLR4 on their surface. Incubation of DC with live, but not inactivated, virus for 2 days resulted in an increase of the total TLR4+ DC to 52%, with only minor changes in the MFI. However, as with the expression of costimulatory molecules, significant changes in the surface expression of TLR4 could not be observed in either live or inactivated virus-treated M{phi}.



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 6. SARS-CoV modulates the expression of TLR4 expression on the surface of M{phi} and DC. Primary M{phi} (A) and DC (B) were mock infected, or infected with inactivated SARS-CoV or live SARS-CoV (MOI = 1) for 2 days before being harvested for analyzing their surface expression of TLR4 molecule by flow cytometry. Data presented are the histogram of FACS analysis showing the percentages of positive cells along with their MFI. Results are representative of two independent experiments using cells derived from different individuals.

 
It was also noted that the ability of DC to secrete IL-12 and IL-6 in response to SARS-CoV does not always parallel with their phenotypic maturation because an enhanced production of both cytokines was also observed in live virus-exposed DC that did not show any phenotypic changes (data not shown). Taken together, these results strongly suggest that not only can SARS-CoV by itself induce the release of cytokines, it can also precondition M{phi} and DC for a highly intense inflammatory response in response to bacterial LPS, resulting in massive inflammatory secretions.

SARS-CoV reduces the receptor-mediated endocytic activity of M{phi} and enhances the T cell stimulatory capacity of DC

The ability to capture and process Ag and to subsequently present antigenic peptides to Ag-specific T cells are characteristic functions of M{phi} and DC (40, 41). Therefore, we investigated whether SARS-CoV could modify these two crucial functions of M{phi} and DC. To study this, we exposed M{phi} and DC to either inactivated or live SARS-CoV (MOI = 1) for a total of 3 days. Parallel cultures of mock-treated cells were also included as controls. Because receptor-mediated endocytosis is the most efficient mechanism for the uptake of Ags (42), we analyzed the effect of SARS-CoV on the mannose receptor-mediated uptake of FITC-conjugated dextran in M{phi}. The endocytosis of various M{phi} populations was assessed by quantifying the total uptake of FITC-dextran probe by flow cytometry. As shown in Fig. 7, an average of two independent experiments, mock-treated M{phi} that were incubated at 4°C did not actively take up FITC-dextran and had a minimal MFI of 37.5 ± 7. However, at physiological temperatures they were quite active in endocytosis with an MFI of 291 ± 55. Interestingly, incubation with live virus reduced the MFI of captured FITC-dextran probes to 108 ± 15. Although the difference in the values of MFI between mock-infected and live virus-infected M{phi} was not statistically significant (p ≤ 0.088), such obvious reduction in the phagocytic activity could be biologically relevant. Inactivated SARS-CoV-exposed M{phi} had a lesser decrease in uptake (MFI = 210 ± 40). These results suggest that infectious SARS-CoV has the ability to compromise the phagocytic activity of M{phi}, decreasing the potential of these cells to present Ags and increasing the threat of opportunistic infections.



View larger version (8K):
[in this window]
[in a new window]
  		FIGURE 7. SARS-CoV reduces the phagocytic activity of M{phi}. Uninfected, live SARS-CoV-infected, and gamma-inactivated SARS-CoV-infected M{phi} (MOI = 1) were incubated in a medium containing FITC-dextran at 37°C (test) 4°C (control) for 45 min. M{phi} were then harvested, thoroughly washed with warm PBS, and analyzed by FACS analysis for the total uptakes of FITC-dextran. The phagocytic activity was expressed as the MFI of endocytosed dextran probe. The results are presented as the average of two independent experiments.

 
The capacity to activate naive T cells is a characteristic feature of mature DC. To determine whether SARS-CoV could also affect the ability of DCs ability to prime naive T cells, DC were exposed to live virus (MOI = 1) or inactivated virus for a total of 3 days, and their ability to stimulate naive CD4+ T cells was analyzed by a standard one-way MLR. As shown in Fig. 8, representative of four independent experiments using DC derived from different individuals, DC exposed to live virus stimulated a very active proliferation of the responder T cells, exceeding 300 times the efficiency of mock or inactivated virus-treated DC. These results are consistent with the expression level of costimulatory molecules, as shown in Fig. 4B, and suggest that live virus is also capable of inducing functional maturation of DC.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 8. SARS-CoV infection enhances the ability of DC to stimulate naive allogeneic T cells. DC were infected with live SARS-CoV or gamma-inactivated SARS-CoV at an MOI of 1, or remained uninfected for a total of 3 days. Differentially treated DC were then harvested, gamma-irradiated (3000 rads), and added to purified allogeneic CD4+ T cells at differential ratios, and cultured in 96-well, U-bottom microtiter plates for a total of 6 days. Individual wells were pulsed with [3H]thymidine a the concentration of 1 µCi/well for the last 12–16 h in the culture. The proliferation of allogeneic T cells was expressed as the average cpm ± SD of triplicate samples. Data shown are representative of four individual experiments. *, p < 0.01 from Student’s t test, compared with mock-infected controls.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the present study we investigated, for the first time, the susceptibility of primary human M{phi} and DC and their subsequent responses to SARS-CoV infection by focusing on their phenotypic expression, secretion of inflammatory cytokines, phagocytic activity, and T cell-priming capacity. The findings of our studies are: 1) SARS-CoV could not productively infect M{phi} and DC (Figs. 1 and 2); 2) incubation with SARS-CoV did not add to the spontaneous cell death of primary M{phi} and DC; on the contrary, it enhanced their viability (Fig. 3) independently of the presence of exogenous cytokines; 3) exposure to live SARS-CoV exerted a diverse effect on the biology of DC vs M{phi}, in which it up-regulated the expression of MHC class II, CD40, CD83, and CD86, on the surface of DC but not M{phi}. Consequently, it also greatly enhanced DC ability to stimulate the proliferation of allogeneic T cells (Figs. 4 and 8). In contrast, it impaired the phagocytic activity of M{phi} (Fig. 7); and 4) not only can live SARS-CoV induce a low-to-moderate production of IL-6 and IL-12, but it also can prime for a much higher production of these proinflammatory cytokines by both M{phi} and DC in response to a suboptimal dose of LPS from Escherichia coli (Fig. 5). Importantly, the ability of SARS-CoV to modulate M{phi} and DC functions was independent of viral replication.

As mentioned, M{phi} and DC are highly susceptible to many viruses. Thus, the prominent accumulation of interstitial and alveolar M{phi} in the lungs of patients severely affected by SARS has raised the possibility that pulmonary M{phi} could be one of the primary targets of SARS-CoV (8). However, the rarely detected viral genome and complete absence of viral Ags or viral particles in pulmonary M{phi}, as revealed by subsequent studies, in which the cellular and tissue distribution of SARS-CoV was examined in postmortem lung tissues by in situ hybridization and immunohistochemistry, strongly suggest that they might function as scavengers rather than as the prime targets for this virus (9, 43). These results are in accordance with our in vitro results, in which no evidence of productive SARS-CoV replication in M{phi} and DC was found. Our conclusion that neither M{phi} nor DC were permissive to in vitro SARS-CoV infection is based on the comparison with the kinetics of infectious virus recovery and the expression level of subgenomic virus-specific mRNA 5 (M protein) in permissive Vero E6 cells. However, our conclusion is in contrast to that of a recent report, in which human monocytic cells in freshly isolated PBMC were shown to be capable of supporting a self-limited SARS-CoV replication with occasionally a maximal one-log increase in the recovery of infectious viral particles over a period of 4 days in infected PBMC cultures (44). Although the exact reason for the discrepancy between our data and those recently reported is not clear, the difference in the differentiation state of the target cells or in the strains of SARS-CoV used in these studies, e.g., the Urbani strain in one and the SIN 2774 isolate in the other, offer possible explanations.

M{phi} and DC play an important role in the destruction of infectious agents and provide a link between innate and adaptive immunity. Ironically, they are also known to serve as vehicles for virus replication and further dissemination, as shown for HIV and measles virus (18, 45). Thus, the nonproductive nature of SARS-CoV infection, as reported in this study, would greatly reduce the likelihood of their role as viral reservoirs for disseminating the infection. However, from the pathological point of view, such a possibility may exist in that it took 5 days or longer for the infectivity of supernatants harvested from infected M{phi} and DC cultures to become undetectable by the TCID50 assay. This gradual loss of SARS-CoV infectivity associated with infected M{phi} and DC cultures, along with an increased viability of these cells in response to SARS-CoV infection (Fig. 3), may thus give them the potential to play some role in further dissemination. Whether infectious viral particles remained bound to the surface at all times or were internalized later after initial contact with cells, as well as other aspects of this nonproductive interaction between SARS-CoV and M{phi} or DC, are the subject of intense investigation in our laboratory. Our preliminary data revealed that although ACE2, the cellular receptor of SARS-CoV, could be detected in both cell types by Western blotting, we were unable to demonstrate its surface expression by flow cytometry (data not shown). CD209L (L-SIGN) has recently been identified as an additional receptor for SARS-CoV (46). Because CD209L is known to express on the surface of primary DC and DC-like KG-1 cells, the failure of SARS-CoV to productively infect these cells in our study indicates that this molecule may not be as critical as ACE2 in mediating SARS-CoV infection in M{phi} and DC.

In addition to viruses and other pathogens, various inflammatory mediators, including LPS, dsRNA, and cytokines (e.g., TNF-{alpha}, IL-1, IL-6, IL-10, and others) can also induce maturation of DC (37). The stocks of SARS-CoV used in our study were derived from infected Vero E6 cells as crude cell-free supernatants, which might contain inflammatory cytokines that were released by infected Vero E6 cells, thus raising a possibility that the observed DC maturation in the current study could be a direct effect of contaminating cytokines in the virus stock rather than one of SARS-CoV infection. This is unlikely, because DC exposed to SARS-CoV from the same stock, which was irradiated by cobalt-60 at a dose (2 x 106 rad) shown to be sufficient to inactivate 107 TCID50/ml SARS-CoV without affecting cytokine activity (data not shown) (47), did not cause any significant phenotypic change. The ability of SARS-CoV to affect DC maturation is apparently dependent on live virus, as incubation with gamma-inactivated virus did not cause phenotypic and functional changes. This observation clearly suggests that a simple cellular receptor-mediated interaction with SARS-CoV is not by itself sufficient to activate DC. It has been reported that the ability to alter DC function by two large DNA viruses, HSV type 1 and human CMV, was mediated through soluble factors induced by immediate early and early gene products of viruses and was independent of a complete viral replication cycle (35, 36). Whether certain SARS-CoV-encoded signals were required for the manipulation of DC function is currently under investigation.

One of the characteristic features of the early stages of SARS is a decrease in the total counts of circulating CD4 and CD8 subsets of T lymphocytes (48). Significantly, the extent of this transient lymphopenia is associated with the severity of SARS. Although the mechanism underlying this hematological manifestation of SARS remains undefined, the sequestration of virus-specific T cells in the lungs or other infected peripheral tissues could result in such a transient loss of circulating T cells. In this context, the effectiveness of SARS-CoV to activate DC may be of significance. DC are known to be the only APCs capable of stimulating Ag-specific naive T cells in the draining lymph nodes, resulting in their expansion. These primed T cells subsequently transmigrate, via the bloodstream, to infected peripheral tissues in which they exert acquired immune functions by killing infected target cells, resulting in tissue damage. Additionally, they can also exacerbate local inflammation by secreting inflammatory cytokines. Thus, the superb ability of live SARS-CoV-exposed DC to prime naive T cells, as shown in this study, may suggest the existence of reasonably active virus-specific effector and/or memory T cell pool in patients recovered from SARS.

The ability of SARS-CoV to impair the phagocytic function of M{phi} is shared by many other viruses, some of which are porcine reproductive and respiratory syndrome virus, an animal coronavirus, respiratory syndrome virus, and HIV (49, 50, 51, 52). Because the outcome of respiratory viral infections is often complicated by secondary bacterial infection (53), the reduced capacity of M{phi} to uptake the invading bacteria and other pathogens could pave the way for enhanced secondary infections, contributing to a situation of devastating pathology in the respiratory system.

It is clear that SARS-CoV induces activation of DC, resulting in phenotypic and functional maturation, as well as cytokine production, whereas its effect on M{phi} seemed to be restricted to selected functions, e.g., phagocytosis and cytokine production. The molecular basis for such a cell type-specific effect of this virus is unknown. SARS-CoV interaction with these cells may occur via the specific receptor, ACE2. Thus, a difference in the level of ACE2 expression between these two cells could thus be responsible for the discrete effect. Alternatively, virus may also interact with these cells via receptor-independent mechanisms, in which the kinetics and/or magnitude of such interactions would be largely based on the activation/differentiation stages of M{phi} vs DC. Thus, a detailed examination of M{phi}/DC-SARS-CoV interactions, especially in the early phase of interaction, is warranted for clarifying the differences in their responses to SARS-CoV infection.

Based on our findings, we propose the following model of SARS-CoV pathogenesis in which M{phi} and DC are of central importance. Alveolar M{phi} and DC residing in the airway epithelium interact with SARS-CoV, either inhaled via the aerosol route or released into airspaces by infected pneumocytes. Although there is not a productive infection, functional alterations occur in these cells. As a consequence of interaction with SARS-CoV, the phagocytic capacity of M{phi} decreases, posing an imminent threat of secondary bacterial and other pathogenic infections, whereas DC are activated, leading to a mature phenotype and subsequent migration from the lung to the lymph nodes where they efficiently stimulate naive T cells. Activated T cells efficiently transmigrate to the sites of pulmonary infection via the bloodstream, and firmly bind to and destroy infected pneumocytes and other permissive cells, causing extensive damage in the lung parenchyma. In addition, the inflammatory cytokines released by activated M{phi} and DC could further exacerbate unfavorable inflammatory responses in the lungs. The markedly enhanced secretion of proinflammatory cytokines by cells exposed to infectious SARS-CoV and low levels of LPS may also occur in the setting of Gram-negative pneumonia, stimulation of other TLR, or activities of transmigrated Ag-specific T cells, further contributing to an unfavorable outcome of SARS.


   Acknowledgments
 
We thank Dr. Li-Kung Chen, Tzu Chi University (Hualien, Taiwan) for kindly supplying convalescence serum for a SARS patient, Drs. Vivian Braciale and Kui Li for critical review of this manuscript, and Mardelle Susman for assistance with the submission of this manuscript.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant NO1 AI25489 (to C.J.P.) and Public Health Service Grant AI29984 (to S.M.). L.A.P. is a Predoctoral Fellow of the McLaughlin Fellowship Fund. Back

2 Address correspondence and reprint requests to Dr. Chien-Te K. Tseng, Department of Microbiology and Immunology, Centers for Biodefense and Emerging Diseases, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0609. E-mail address: sktseng{at}utmb.edu Back

3 Abbreviations used in this paper: SARS, severe acute respiratory syndrome; CoV, coronavirus; DC, dendritic cell; M{phi}, macrophage; ACE, angiotensin-converting enzyme; TCID50, 50% tissue culture infectious dose; MOI, multiplicity of infection; MFI, mean fluorescence intensity. Back

Received for publication December 14, 2004. Accepted for publication March 31, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. WHO issues consensus document on the epidemiology of SARS. Wkly. Epidemiol. Rec. 78:2003 373-375.[Medline]
  2. Drosten, C., S. Gunther, W. Preiser, W. S. van der, H. R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. Fouchier, et al 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1967-1976.[Abstract/Free Full Text]
  3. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, J. A. Comer, W. Lim, et al 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348: 1953-1966.[Abstract/Free Full Text]
  4. Peiris, J. S., S. T. Lai, L. L. Poon, Y. Guan, L. Y. Yam, W. Lim, J. Nicholls, W. K. Yee, W. W. Yan, M. T. Cheung, et al 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.[Medline]
  5. Marra, M. A., S. J. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. Butterfield, J. Khattra, J. K. Asano, S. A. Barber, S. Y. Chan, et al 2003. The Genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404.[Abstract/Free Full Text]
  6. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, et al 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399.[Abstract/Free Full Text]
  7. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, et al 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426: 450-454.[Medline]
  8. Nicholls, J. M., L. L. Poon, K. C. Lee, W. F. Ng, S. T. Lai, C. Y. Leung, C. M. Chu, P. K. Hui, K. L. Mak, W. Lim, et al 2003. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361: 1773-1778.[Medline]
  9. To, K. F., J. H. Tong, P. K. Chan, F. W. Au, S. S. Chim, K. C. Chan, J. L. Cheung, E. Y. Liu, G. M. Tse, A. W. Lo, et al 2004. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J. Pathol. 202: 157-163.[Medline]
  10. Jones, B. M., E. S. Ma, J. S. Peiris, P. C. Wong, J. C. Ho, B. Lam, K. N. Lai, K. W. Tsang. 2004. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin. Exp. Immunol. 135: 467-473.[Medline]
  11. Wong, C. K., C. W. Lam, A. K. Wu, W. K. Ip, N. L. Lee, I. H. Chan, L. C. Lit, D. S. Hui, M. H. Chan, S. S. Chung, J. J. Sung. 2004. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 136: 95-103.[Medline]
  12. Li, Z., X. Guo, W. Hao, Y. Wu, Y. Ji, Y. Zhao, F. Liu, X. Xie. 2003. The relationship between serum interleukins and T-lymphocyte subsets in patients with severe acute respiratory syndrome. Chin. Med. J. 116: 981-984.[Medline]
  13. Xie, J., Y. Han, T. S. Li, Z. F. Qiu, X. J. Ma, H. W. Fan, W. Lu, Z. Y. Liu, Z. Wang, H. L. Wang, G. H. Deng. 2003. [Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome]. Zhonghua Nei. Ke. Za. Zhi. 42: 643-645.[Medline]
  14. Kaiserlian, D., B. Dubois. 2001. Dendritic cells and viral immunity: friends or foes?. Semin. Immunol. 13: 303-310.[Medline]
  15. Ardavin, C., G. M. del Hoyo, P. Martin, F. Anjuere, C. F. Arias, A. R. Marin, S. Ruiz, V. Parrillas, H. Hernandez. 2001. Origin and differentiation of dendritic cells. Trends Immunol. 22: 691-700.[Medline]
  16. Andrews, D. M., C. E. Andoniou, F. Granucci, P. Ricciardi-Castagnoli, M. A. Degli-Esposti. 2001. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat. Immunol. 2: 1077-1084.[Medline]
  17. Hahn, G., R. Jores, E. S. Mocarski. 1998. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. USA 95: 3937-3942.[Abstract/Free Full Text]
  18. Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M. C. Rissoan, Y. J. Liu, C. Rabourdin-Combe. 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J. Exp. Med. 186: 813-823.[Abstract/Free Full Text]
  19. Humlova, Z., M. Vokurka, M. Esteban, Z. Melkova. 2002. Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol. 83: 2821-2832.[Abstract/Free Full Text]
  20. Bruinink, A., O. Haller. 1979. Macrophage immunity to influenza virus: in vitro and in vivo studies. Exp. Cell Biol. 47: 190-201.[Medline]
  21. Libraty, D. H., S. Pichyangkul, C. Ajariyakhajorn, T. P. Endy, F. A. Ennis. 2001. Human dendritic cells are activated by dengue virus infection: Enhancement by {gamma} interferon and implications for disease pathogenesis. J. Virol. 75: 3501-3508.[Abstract/Free Full Text]
  22. Miller, G., S. Lahrs, V. G. Pillarisetty, A. B. Shah, R. P. DeMatteo. 2002. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res. 62: 5260-5266.[Abstract/Free Full Text]
  23. Biggs, B. A., M. Hewish, S. Kent, K. Hayes, S. M. Crowe. 1995. HIV-1 infection of human macrophages impairs phagocytosis and killing of Toxoplasma gondii. J. Immunol. 154: 6132-6139.[Abstract]
  24. Kedzierska, K., P. Ellery, J. Mak, S. R. Lewin, S. M. Crowe, A. Jaworowski. 2002. HIV-1 down-modulates {gamma} signaling chain of Fc{gamma}R in human macrophages: a possible mechanism for inhibition of phagocytosis. J. Immunol. 168: 2895-2903.[Abstract/Free Full Text]
  25. Wunschmann, S., B. Becker, A. Vallbracht. 2002. Hepatitis A virus suppresses monocyte-to-macrophage maturation in vitro. J. Virol. 76: 4350-4356.[Abstract/Free Full Text]
  26. Orenstein, J. M.. 2001. The macrophage in HIV infection. Immunobiology 204: 598-602.[Medline]
  27. Way, S. J., B. A. Lidbury, J. L. Banyer. 2002. Persistent Ross River virus infection of murine macrophages: an in vitro model for the study of viral relapse and immune modulation during long-term infection. Virology 301: 281-292.[Medline]
  28. Tseng, C. T., G. R. Klimpel. 2002. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195: 43-49.
  29. Akagawa, K. S.. 2002. Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int. J. Hematol. 76: 27-34.[Medline]
  30. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, G. Schuler. 1996. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137-151.[Medline]
  31. Zhou, L. J., T. F. Tedder. 1996. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA 93: 2588-2592.[Abstract/Free Full Text]
  32. Tseng, C. T., E. Miskovsky, M. Houghton, G. R. Klimpel. 2001. Characterization of liver T-cell receptor {gamma}{delta} T cells obtained from individuals chronically infected with hepatitis C virus (HCV): evidence for these T cells playing a role in the liver pathology associated with HCV infections. Hepatology 33: 1312-1320.[Medline]
  33. Tseng, C. T., E. Miskovsky, G. R. Klimpel. 2001. Crosslinking CD81 results in activation of TCR{gamma}{delta} T cells. Cell. Immunol. 207: 19-27.[Medline]
  34. Cheung, C. Y., L. L. Poon, A. S. Lau, W. Luk, Y. L. Lau, K. F. Shortridge, S. Gordon, Y. Guan, J. S. Peiris. 2002. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 360: 1831-1837.[Medline]
  35. Beck, K., U. Meyer-Konig, M. Weidmann, C. Nern, F. T. Hufert. 2003. Human cytomegalovirus impairs dendritic cell function: a novel mechanism of human cytomegalovirus immune escape. Eur. J. Immunol. 33: 1528-1538.[Medline]
  36. Kruse, M., O. Rosorius, F. Kratzer, G. Stelz, C. Kuhnt, G. Schuler, J. Hauber, A. Steinkasserer. 2000. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J. Virol. 74: 7127-7136.[Abstract/Free Full Text]
  37. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.[Medline]
  38. Lipscomb, M. F., B. J. Masten. 2002. Dendritic cells: immune regulators in health and disease. Physiol. Rev. 82: 97-130.[Abstract/Free Full Text]
  39. Chen, P., J. Li, J. Barnes, G. C. Kokkonen, J. C. Lee, Y. Liu. 2002. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J. Immunol. 169: 6408-6416.[Abstract/Free Full Text]
  40. Banchereau, J., R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.[Medline]
  41. Thomas, R., L. S. Davis, P. E. Lipsky. 1993. Comparative accessory cell function of human peripheral blood dendritic cells and monocytes. J. Immunol. 151: 6840-6852.[Abstract]
  42. Lanzavecchia, A.. 1990. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu. Rev. Immunol. 8: 773-793.[Medline]
  43. Nakajima, N., Y. Asahi-Ozaki, N. Nagata, Y. Sato, F. Dizon, F. J. Paladin, R. M. Olveda, T. Odagiri, M. Tashio, T. Sata. 2003. SARS coronavirus-infected cells in lung detected by new in situ hybridization technique. Jpn. J. Infect. Dis. 56: 139-141.[Medline]
  44. Huang, C. B., Q. Wang, G. Q. Xie, A. H. Liu, B. Lai, Y. J. Chen, Y. J. Cheng, H. Xu, D. M. Han. 2004. [Immunological characteristics of 1291 cases of severe acute respiratory syndrome in Beijing]. Zhonghua Nei. Ke. Za. Zhi. 43: 406-409.[Medline]
  45. Granelli-Piperno, A., V. Finkel, E. Delgado, R. M. Steinman. 1999. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Curr. Biol. 9: 21-29.[Medline]
  46. Jeffers, S. A., S. M. Tusell, L. Gillim-Ross, E. M. Hemmila, J. E. Achenbach, G. J. Babcock, W. D. Thomas, Jr, L. B. Thackray, M. D. Young, R. J. Mason, et al 2004. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. USA 101: 15748-15753.[Abstract/Free Full Text]
  47. Mahanty, S., R. Kalwar, P. E. Rollin. 1999. Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. J. Med. Virol. 59: 341-345.[Medline]
  48. Wong, R. S., A. Wu, K. F. To, N. Lee, C. W. Lam, C. K. Wong, P. K. Chan, M. H. Ng, L. M. Yu, D. S. Hui, et al 2003. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br. Med. J. 326: 1358-1362.[Abstract/Free Full Text]
  49. Solano, G. I., E. Bautista, T. W. Molitor, J. Segales, C. Pijoan. 1998. Effect of porcine reproductive and respiratory syndrome virus infection on the clearance of Haemophilus parasuis by porcine alveolar macrophages. Can. J. Vet. Res. 62: 251-256.[Medline]
  50. Riber, U., J. Nielsen, P. Lind. 2004. In utero infection with PRRS virus modulates cellular functions of blood monocytes and alveolar lung macrophages in piglets. Vet. Immunol. Immunopathol. 99: 169-177.[Medline]
  51. Guerrero-Plata, A., E. Ortega, B. Gomez. 2001. Persistence of respiratory syncytial virus in macrophages alters phagocytosis and pro-inflammatory cytokine production. Viral Immunol. 14: 19-30.[Medline]
  52. Torre, D., L. Gennero, F. M. Baccino, F. Speranza, G. Biondi, A. Pugliese. 2002. Impaired macrophage phagocytosis of apoptotic neutrophils in patients with human immunodeficiency virus type 1 infection. Clin. Diagn. Lab. Immunol. 9: 983-986.[Abstract/Free Full Text]
  53. Babiuk, L. A., M. J. Lawman, H. B. Ohmann. 1988. Viral-bacterial synergistic interaction in respiratory disease. Adv. Virus Res. 35: 219-249.[Medline]



This article has been cited by other articles:


Home page
 J. Virol.Home page
N. Yoshikawa, T. Yoshikawa, T. Hill, C. Huang, D. M. Watts, S. Makino, G. Milligan, T. Chan, C. J. Peters, and C.-T. K. Tseng
Differential Virological and Immunological Outcome of Severe Acute Respiratory Syndrome Coronavirus Infection in Susceptible and Resistant Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2
J. Virol., June 1, 2009; 83(11): 5451 - 5465.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Yoshikawa, T. Hill, K. Li, C. J. Peters, and C.-T. K. Tseng
Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells
J. Virol., April 1, 2009; 83(7): 3039 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Netland, D. K. Meyerholz, S. Moore, M. Cassell, and S. Perlman
Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2
J. Virol., August 1, 2008; 82(15): 7264 - 7275.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Gu and C. Korteweg
Pathology and Pathogenesis of Severe Acute Respiratory Syndrome
Am. J. Pathol., April 1, 2007; 170(4): 1136 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C.-T. K. Tseng, C. Huang, P. Newman, N. Wang, K. Narayanan, D. M. Watts, S. Makino, M. M. Packard, S. R. Zaki, T.-s. Chan, et al.
Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor
J. Virol., February 1, 2007; 81(3): 1162 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. Spiegel, K. Schneider, F. Weber, M. Weidmann, and F. T. Hufert
Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells
J. Gen. Virol., July 1, 2006; 87(7): 1953 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Ziegler, S. Matikainen, E. Ronkko, P. Osterlund, M. Sillanpaa, J. Siren, R. Fagerlund, M. Immonen, K. Melen, and I. Julkunen
Severe Acute Respiratory Syndrome Coronavirus Fails To Activate Cytokine-Mediated Innate Immune Responses in Cultured Human Monocyte-Derived Dendritic Cells
J. Virol., November 1, 2005; 79(21): 13800 - 13805.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tseng, C.-T. K.
Right arrow Articles by Peters, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tseng, C.-T. K.
Right arrow Articles by Peters, C. J.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS